10/07/2025
A 2024 clinical trial in aging dogs combined a senolytic and an NAD⁺ precursor. It measured cognitive improvement after 3 months.
Though dogs are not humans, the trial underscores a trend: targeting two core aging pathways can deliver additive benefits.
Here’s how that supports Senolyte™ principles:
+ If combined therapies show benefits in mammals, human translations become more plausible.
+ It points to dosage windows, safety margins, and timeframes to monitor.
+ It also suggests that biomarkers (cognition, frailty, activity) need to be primary endpoints in aging research.
Takeaway: when you evaluate or design formulations, look for evidence of synergy—not just additive claims.
Learn more about Senolytics : www.eca-senolyte.com
Source: https://www.nature.com/articles/s41598-024-63031-w?utm_source=chatgpt.com